Managing Bleeds on Anticoagulant Therapy

Bleeding remains the most significant and frequent complication of oral anticoagulant (OAC) therapy, with real consequences for patient outcomes and thromboembolic risk.

Direct oral anticoagulants (DOACs) provide better intracranial bleeding protection than vitamin K antagonists (VKAs), but may increase gastrointestinal bleeding risk. Combination antithrombotic therapy compounds bleeding hazards, necessitating careful patient selection and regular reassessment using validated scoring tools like HAS-BLED and PRECISE-HBR.

Flowchart for the acute management of bleeding in patients on anticoagulant therapy, from initial assessment through the major-versus-non-major bleeding decision, reversal, source control, and restarting anticoagulation — Fig. 1 — Pragmatic algorithm for the acute management of bleeding in patients receiving anticoagulant therapy.

Critical Bleeding

For situations involving hemodynamic instability or critical anatomical sites, the recommended approach is urgent stabilization, antithrombotic discontinuation, targeted resuscitation, and drug-specific reversal agents: idarucizumab for dabigatran; andexanet alfa or PCC for FXa inhibitors; and vitamin K plus PCC for VKAs.

Multidisciplinary involvement matters, and restarting anticoagulation after major bleeding — once hemostasis is achieved — should be prioritized, balancing thrombotic versus bleeding risk with potential dose adjustments.

Table listing major critical-site bleeding locations (intracranial, intraocular, pericardial, gastrointestinal, retroperitoneal, airway, genitourinary, musculoskeletal), their pathophysiologic rationale, and immediate management priorities — Table 3 — Major critical-site bleeding: clinical features, pathophysiology, and immediate management priorities.

Table of specific reversal agents for antiplatelet and anticoagulant therapies, including UFH, LMWH, fondaparinux, VKA, dabigatran, and FXa inhibitors, with mechanism, reversal agent, dosing and onset, and clinical considerations — Table 5 — Specific reversal agents for antiplatelet and anticoagulant therapies.

Minor Bleeding

Minor bleeding typically requires supportive care rather than therapy cessation.

Source discussed: management of bleeding on anticoagulant therapy.

Managing Bleeds On Anticoagulant Therapy

Critical Bleeding

Minor Bleeding

Turn Articles Like This Into CME Credit.